Atrial fibrillation, inflammation and statins

Hellenic Journal of Cardiology

Volumn 47, Issue 2, 2006, Pages 51-53

  Ganotakis, Emmanuel S ^a   Mikhailidis, Dimitri P ^a   Vardas, Panos E ^b  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Atrial remodelling; Dyslipidaemia

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; EDITORIAL; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART SURGERY; HUMAN; HYPERTENSION; INFLAMMATION; METABOLIC SYNDROME X; MORTALITY; OBESITY; STROKE;

EID: 33646893889     PISSN: 10117970     EISSN: 10117970     Source Type: Journal    
DOI: None     Document Type: Editorial

References (37)

1. Ray IB, Heist EK: Treating atrial fibrillation. What is the consensus now? Postgrad Med 2005; 118: 47-48, 51-54, 58.
2. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG: Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995; 155: 469-473.
3. American College of Chest Physicians guidelines for prevention and management of postoperative atrial fibrillation after cardiac surgery. www.guideline.gov.
4. Ahmari SA, Bunch TJ, Chandra A, et al: Prevalence, pathophysiology, and clinical significance of post-heart transplant atrial fibrillation and atrial flutter. J Heart Lung Transplant 2006; 25: 53-60.
5. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991; 22: 983-988.
6. Benjamin EJ, Levy D, Vaziri SM, et al: Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA 1994; 271: 840-844.
7. Go AS, Fang MC, Singer DE: Antithrombotic therapy for stroke prevention in atrial fibrillation. Prog Cardiovasc Dis 2005; 48: 108-124.
8. Nattel S, Shiroshita-Tkeshita A, Brundel BJ, Rivard L: Mechanisms of atrial fibrillation: lessons from animal models. Prog Cardiovasc Dis 2005; 48: 9-28.
9. Oral H: Mechanisms of atrial fibrillation: lessons from studies in patients. Prog Cardiovasc Dis. 2005; 48: 29-40.
10. Korantzopoulos P, Kolettis T, Siogas K, Goudevenos J: Atrial fibrillation and electrical remodeling: the potential role of inflammation and oxidative stress. Med Sci Monit 2003; 9: RA 225-229.
11. Olshansky B: Interrelationships between the autonomic nervous system and atrial fibrillation. Prog Cardiovasc Dis 2005; 48: 57-78.
12. Palardy M, Ducharme A: Inhibition of the renin-angiotensin system and atrial fibrillation in heart failure. Heart Drug 2005; 5: 214-219.
13. Ostgren CJ, Merlo J, Rastam L, Lindblad U: Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community. Diabetes Obes Metab 2004; 6: 367-374.
14. Rienstra M, Van Veldhuisen DJ, Hagens VE, et al: Gender-related differences in rhythm control treatment in persistent atrial fibrillation. Data of the rate control versus electrical cardioversion (RACE) study. J Am Coll Cardiol 2005; 46: 1298-1306.
15. Zacharias A, Schwann TA, Riordan CJ, Durham SJ, Shah AS, Habib RH: Obesity and risk of new-onset atrial fibrillation after cardiac surgery. Circulation 2005; 112: 3247-3255.
16. Nicolaou VN, Papadakis JE, Karatzis EN, Dermitzaki SI, Tsakiris AK, Skoufas PD: Impact of the metabolic syndrome on atrial size in patients with new onset atrial fibrillation. Angiology 2006; (in press).
17. Aviles RJ, Martin DO, Apperson-Hancen C, et al: Inflammation as a risk factor for atrial fibrillation. Circulation 2003; 108: 3006-3010.
18. Nattel S, Khairy P, Roy D, et al: New approaches to atrial fibrillation management: a critical review of a rapidly evolving field. Drugs 2002; 62: 2377-2397.
19. Goldstein RN, Stambler BS: New antiarrhythmic drugs for prevention of atrial fibrillation. Prog Cardiovasc Dis 2005; 48: 193-208.
20. Rosenfeld LE. Atrial fibrillation: how to approach rate control: Curr Cardiol Rep 2005; 7: 391-397.
21. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ: Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(suppl 3): 429S-456S.
22. Chung MK, Martin DO, Sprecher D, et al: C-reactive protein elevation in patients with arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104: 2886-2891.
23. Malouf JF, Kanagala R, Al Atawi FO, et al: High sensitivity C-reactive protein; a novel predictor for recurrence of atrial fibrillation after successful cardioversion. J Am Coll Cardiol 2005; 46: 1284-1287.
24. Engelmann MD, Svendsen JH: Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 2005; 26: 2083-2092.
25. Sesso HD, Burning JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM: C-reactive protein and the risk of developing hypertension JAMA 2003; 290: 2945-2951.
26. Shiroshita-Takeshita A, Scram G, Lavoie J, et al: Effects of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 2004; 110: 2313-2319.
27. Kumagai K, Nakashima H, Saku K: The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in canine sterile pericarditis model. Cardiovasc Res 2004; 62: 105-111.
28. Dotani MI, Elnicki DM, Jain AC, et al: Effect of preoperative statin therapy and cardiac outcomes after coronary bypass grafting. Am J Cardiol 2000; 86: 1128-1130.
29. Amar D, Zhang H, Heerdt PM, Park B, Fleisher M, Thaler HT: Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C-reactive protein. Chest 2005; 128: 3421-3427.
30. Young-Xu Y, Jabbour S, Goldberg R, et al: Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003; 92: 1379-1383.
31. Siu CW, Lau CP, Tse HF: Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2004; 92: 1343-1345.
32. Dilaveris P, Giannopoulos G, Synetos A, Stefanadis C: The role of renin angiotensin system blockade in the treatment of atrial fibrillation. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5: 387-403.
33. Bourassa MG: Angiotensin II inhibition and prevention of atrial fibrillation and stroke. J Am Coll Cardiol 2005; 45: 720-721.
34. Lozano HF, Conde CA, Florin T, Lamas GA: Treatment and prevention of atrial fibrillation with nonantiarrhythmic pharmacologic therapy. Heart Rhythm 2005; 2: 1000-1007.
35. Yamagishi S, Takenaka K, Inoue H: Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type receptor blocker in preventing the development of atrial fibrillation. Med Hypotheses 2006; 66: 118-120.
36. Daskalopoulou SS, Mikhailidis DP, Elisaf M: Prevention and treatment of the metabolic syndrome. Angiology 2004; 55: 589-612.
37. Conay DS, Lip GYH: Comparison of outcomes of patients with symptomatic peripheral artery disease with and without atrial fibrillation (the West Birmingham Atrial Fibrillation Project). Am J Cardiol 2004; 93: 1422-1425.